Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07606820

Enrollment

Registered

2026-05-26

Start date

2025-10-29

Completion date

2026-04-30

Last updated

2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

A Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

Interventions

DRUGCrisugabalin(HSK16149)20mg BID

different dose

DRUGCrisugabalin(HSK16149) 20mg qd

different dose

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of rosacea according to the criteria established by the ROSacea COnsensus (ROSCO) 2019 guidelines. * Presence of obvious facial erythema accompanied by significant burning and tingling sensations, with subjective symptoms (e.g., burning and tingling) being more severe than the observable clinical signs. * Refractory facial erythema despite conventional treatment, including antibiotics (metronidazole, doxycycline, and minocycline), oral isotretinoin, and oral beta-blockers.

Exclusion criteria

* Facial inflammatory dermatoses such as acne, contact dermatitis, seborrheic dermatitis, or other facial skin diseases. * Pregnancy or lactation. * Hepatic or renal insufficiency. * Ongoing treatment with long-term topical glucocorticoids or retinoids.

Design outcomes

Primary

Measure	Time frame	Description
CEA	baseline and 4w after treatment	Rosacea Facial Erythema Score

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026